ghk-cu injection human clinical trial Frontiers Injectable Peptides for Anti-Aging? A

Theres not strong evidence supporting systemic regeneration claims as presented online, especially when combining with other experimental peptides

Research has shown that GHK Cu: Downregulates TGF-beta1 (the primary pro-fibrotic cytokine) in fibrotic cell models Upregulates decorin a proteoglycan that inhibits TGF-beta1 signalling and organises collagen fibril structure Reduces expression of MMP inhibitors, allowing physiological matrix remodelling to proceed This dual action promoting organised collagen synthesis in healing wounds while suppressing dysregulated fibrotic collagen makes GHK Cu of interest in research models of skin fibrosis, liver fibrosis, and lung fibrosis

Split larger volumes into smaller portions to improve comfort and reduce bathroom urgency

Higher bioavailability More NAD+ is available for cellular use compared to oral supplements